Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2016

01-04-2016 | Review

A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis

Authors: Tomohiro F. Nishijima, Maya Suzuki, Hyman B. Muss

Published in: Breast Cancer Research and Treatment | Issue 2/2016

Login to get access

Abstract

Capecitabine 1000 mg/m2 bid × 14 days every 21 days (14/21) has been reported to have similar efficacy but more favorable toxicity profile than the approved dosage of 1250 mg/m2. However, a dose-toxicity relationship of capecitabine in breast cancer patients has not been fully elucidated. We performed a systematic review and meta-analysis to compare a safety profile between capecitabine starting dose of 1000 and 1250 mg/m2 bid. Studies were identified using PubMed, ASCO, and San Antonio Breast Cancer Symposium abstract databases through December 2015. Eligible trials included phase II/III trials of capecitabine monotherapy at 1000 or 1250 mg/m2 bid (14/21) for breast cancer patients that reported adequate safety data for all (grade 1–4) or high (grade 3–4) grade hand foot syndrome (HFS), diarrhea, fatigue, nausea, vomiting, stomatitis, neutropenia, thrombocytopenia, or anemia, as well as dose reductions, treatment discontinuation or treatment-related deaths. The summary incidence was calculated using random-effects models. A total of 4833 patients from 34 trials were included. 1218 and 3615 patients were treated with capecitabine 1000 and 1250 mg/m2 bid, respectively. A significantly lower incidence of dose reduction (15.9 vs. 39.0 %; P = 0.007), high-grade HFS (12.0 vs. 19.0 %; P = 0.01), diarrhea (5.3 vs. 9.1 %; P = 0.01), and neutropenia (1.8 vs. 7.3 %; P < 0.01), and all-grade neutropenia (5.8 vs. 25.4 %; P = 0.01) was seen in capecitabine 1000 mg/m2 compared to 1250 mg/m2. Capecitabine monotherapy at 1000 mg/m2 bid (14/21) has a clinically meaningful and significantly better toxicity profile compared to 1250 mg/m2 bid (14/21).
Literature
1.
Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K et al (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34(8):1274–1281CrossRefPubMed
2.
3.
Blum JL, Barrios CH, Feldman N, Verma S, McKenna EF, Lee LF et al (2012) Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer. Breast Cancer Res Treat 136(3):777–788CrossRefPubMed
4.
O’Shaughnessy JA, Kaufmann M, Siedentopf F, Dalivoust P, Debled M, Robert NJ et al (2012) Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer. Oncologist 17(4):476–484CrossRefPubMedPubMedCentral
5.
Pallis AG, Boukovinas I, Ardavanis A, Varthalitis I, Malamos N, Georgoulias V et al (2012) A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Ann Oncol 23(5):1164–1169CrossRefPubMed
6.
Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23(4):792–799CrossRefPubMed
7.
El-Helw L, Coleman RE (2005) Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer. Breast 14(5):368–374CrossRefPubMed
8.
Baselga J, Segalla JG, Roche H, Del Giglio A, Pinczowski H, Ciruelos EM et al (2012) Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol 30(13):1484–1491CrossRefPubMed
9.
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62(10):1006–1012CrossRefPubMed
10.
11.
Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101CrossRefPubMed
12.
13.
Goldstein LJ, Oliveira CT, Heinrich B, Stemmer SM, Mala C, Kastner S, et al (2013) A randomized double-blind phase II study of the combination of oral WX-671 plus capecitabine versus capecitabine monotherapy in first-line HER2-negative metastatic breast cancer (MBC). J Clin Oncol 31 (suppl; abstr 508)
14.
Lee SJ, Toi M, Lee ES, Ohtani S, Im YH, Im SA, Park BW, et al (2015) A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). San Antonio Breast Cancer Symposium. Abstract S1-07
15.
Bajetta E, Procopio G, Celio L, Gattinoni L, Della Torre S, Mariani L et al (2005) Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 23(10):2155–2161CrossRefPubMed
16.
Rossi D, Alessandroni P, Catalano V, Giordani P, Fedeli SL, Fedeli A et al (2007) Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer. Clin Breast Cancer 7(11):857–860CrossRefPubMed
17.
Barrios CH, Liu MC, Lee SC, Vanlemmens L, Ferrero JM, Tabei T et al (2010) Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 121(1):121–131CrossRefPubMedPubMedCentral
18.
Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A et al (2001) Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92(7):1759–1768CrossRefPubMed
19.
Oshaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D et al (2001) Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12(9):1247–1254CrossRefPubMed
20.
Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C et al (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17(2):485–493PubMed
21.
Jakob A, Bokemeyer C, Knop S, Schupp M, Mayer F, Kanz L (2002) Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation–a phase II study. Anticancer Drugs 13(4):405–410CrossRefPubMed
22.
Talbot DC, Moiseyenko V, Van Belle S, O’Reilly SM, Alba Conejo E, Ackland S et al (2002) Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 86(9):1367–1372CrossRefPubMedPubMedCentral
23.
Reichardt P, Von Minckwitz G, Thuss-Patience PC, Jonat W, Kolbl H, Janicke F et al (2003) Multicenter phase II study of oral capecitabine (Xeloda(“)) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 14(8):1227–1233CrossRefPubMed
24.
Fumoleau P, Largillier R, Clippe C, Dieras V, Orfeuvre H, Lesimple T et al (2004) Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40(4):536–542CrossRefPubMed
25.
Wist EA, Sommer HH, Ostenstad B, Risberg T, Bremnes Y, Mjaaland I (2004) Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncol 43(2):186–189CrossRefPubMed
26.
Lee SH, Lee J, Park J, Park SH, Lee KE, Lee SI et al (2004) Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Med Oncol 21(3):223–231CrossRefPubMed
27.
Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG et al (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112(3):533–543CrossRefPubMed
28.
von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE et al (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 27(12):1999–2006CrossRef
29.
Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB et al (2009) Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 360(20):2055–2065CrossRefPubMedPubMedCentral
30.
Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF et al (2010) Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat 122(2):409–418CrossRefPubMed
31.
Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C et al (2010) Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 28(20):3256–3263CrossRefPubMedPubMedCentral
32.
Kaufmann M, Maass N, Costa SD, Schneeweiss A, Loibl S, Sutterlin MW et al (2010) First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial. Eur J Cancer 46(18):3184–3191CrossRefPubMed
33.
Clemons M, Joy AA, Abdulnabi R, Kotliar M, Lynch J, Jordaan JP et al (2010) Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy. Breast Cancer Res Treat 124(1):177–186CrossRefPubMed
34.
Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON et al (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29(10):1252–1260CrossRefPubMed
35.
Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland SP, Fitzharris B et al (2011) Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol 29(34):4498–4504CrossRefPubMed
36.
Huang H, Jiang Z, Wang T, Zhang S, Bian L, Cao Y et al (2012) Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer. Anticancer Drugs 23(7):718–723CrossRefPubMed
37.
Crown JP, Dieras V, Staroslawska E, Yardley DA, Bachelot T, Davidson N et al (2013) Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol 31(23):2870–2878CrossRefPubMed
38.
Arowolo OA, Njiaju UO, Ogundiran TO, Abidoye O, Lawal OO, Obajimi M et al (2013) Neo-adjuvant capecitabine chemotherapy in women with newly diagnosed locally advanced breast cancer in a resource-poor setting (Nigeria): efficacy and safety in a phase II feasibility study. Breast J 19(5):470–477PubMed
39.
Tolaney SM, Jeong J, Guo H, Brock J, Morganstern D, Come SE et al (2014) A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer. Cancer Med 3(2):293–299CrossRefPubMedPubMedCentral
40.
Mita MM, Joy AA, Mita A, Sankhala K, Jou YM, Zhang D et al (2014) Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer. Clin Breast Cancer 14(3):169–176CrossRefPubMed
41.
Smorenburg CH, de Groot SM, van Leeuwen-Stok AE, Hamaker ME, Wymenga AN, de Graaf H et al (2014) A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG. Ann Oncol 25(3):599–605CrossRefPubMedPubMedCentral
42.
Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G et al (2015) Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 33(6):594–601CrossRefPubMedPubMedCentral
43.
Martin M, Martinez N, Ramos M, Calvo L, Lluch A, Zamora P et al (2015) Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis. Oncologist 20(2):111–112CrossRefPubMedPubMedCentral
44.
Sterne JA, Gavaghan D, Egger M (2000) Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 53(11):1119–1129CrossRefPubMed
45.
Hennessy BT, Gauthier AM, Michaud LB, Hortobagyi G, Valero V (2005) Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol 16(8):1289–1296CrossRefPubMed
46.
Jäger E, Al-Batran S, Saupe S, Schmidt R, Kreienberg LM, Otremba BJ et al (2010) A randomized phase III study evaluating pegylated liposomal doxorubicin (PLD) versus capecitabine (CAP) as first-line therapy for metastatic breast cancer (MBC): results of the PELICAN study. J Clin Oncol 28(15 suppl):1022
47.
Ambros T, Zeichner SB, Zaravinos J, Montero AJ, Ahn E, Aruna M et al (2014) A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer. Breast Cancer Res Treat 146(1):7–14CrossRefPubMed
48.
Bertelsen C, Ji L, Garcia A, Russell C, Spicer D, Sposto R et al (2014) Efficacy of very-low-dose capecitabine in metastatic breast cancer. Am J Hematol 11(2):20–30
49.
Harvey VJ, Sharples KJ, Isaacs RJ, Jameson MB, Jeffery GM, McLaren BR et al (2013) A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclox II. Ann Oncol 24(7):1828–1834CrossRefPubMed
50.
Fedele P, Marino A, Orlando L, Schiavone P, Nacci A, Sponziello F et al (2012) Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer. Eur J Cancer 48(1):24–29CrossRefPubMed
51.
Saeki T, Kimura T, Toi M, Taguchi T (2006) A pilot phase II study of capecitabine in advanced or recurrent breast cancer. Breast Cancer 13(1):49–57CrossRefPubMed
52.
Kusama M, Nomizu T, Aogi K, Yoshimoto M, Horikoshi N, Tabei T et al (2010) Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer. Breast Cancer 17(4):233–240CrossRefPubMed
53.
Taguchi T, Nakayama T, Masuda N, Yoshidome K, Akagi K, Nishida Y et al (2010) Study of low-dose capecitabine monotherapy for metastatic breast cancer. Chemotherapy 56(2):166–170CrossRefPubMed
54.
Traina TA, Theodoulou M, Feigin K, Patil S, Tan KL, Edwards C et al (2008) Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. J Clin Oncol 26(11):1797–1802CrossRefPubMed
55.
Muss HB, Berry DA, Cirrincione C, Budman DR, Henderson IC, Citron ML et al (2007) Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B experience. J Clin Oncol 25(24):3699–3704CrossRefPubMed
56.
Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP et al (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 29(25):3457–3465CrossRefPubMedPubMedCentral
Metadata
Title
A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis
Authors
Tomohiro F. Nishijima
Maya Suzuki
Hyman B. Muss
Publication date
01-04-2016
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2016
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-3756-5

Other articles of this Issue 2/2016

Breast Cancer Research and Treatment 2/2016 Go to the issue

Epidemiology

The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients

Clinical trial

Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27

Epidemiology

Very low local recurrence rates after breast-conserving therapy: analysis of 8485 patients treated over a 28-year period

Erratum

Erratum to: Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients

Clinical trial

A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors

Clinical trial

Should the hyperechogenic halo around malignant breast lesions be included in the measurement of tumor size?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits